Informations générales (source: ClinicalTrials.gov)
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
Interventional
Phase 1/Phase 2
Corbus Pharmaceuticals Inc. (Voir sur ClinicalTrials)
avril 2024
janvier 2027
02 février 2026
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for
participants with solid tumors that are expressing a protein called nectin-4.
The main questions it aims to answer are:
What is the the safe and effective dose of CRB-701? What cancers can be treated
effectively with CRB-701?
Participants will be asked to attend clinic and be given a intravenous infusion of
CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure
whether CRB-701 has an effect on tumors.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Yohann LORIOT | 24/04/2026 15:35:05 | Contacter | ||
Critères
Tous
- Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid
tumors that have progressed having exhausted all appropriate lines of therapy or
have no other standard therapy with proven clinical benefit. In Part C, HNSCC
participants may enroll as first-line therapy.
Exclusion Criteria:
- Active of uncontrolled CNS metastases
- History of solid tumors other than the diseases under study
- History of and/or current cardiovascular events or conditions in the previous 6
months
- Pre-existing >/= Grade 2 neuropathy
- Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic
neuropathy
- Active ocular disease at baseline
- Chronic severe liver disease or live cirrhosis
- Interstitial lung disease or pneumonitis within 6 months on initiating treatment on
study
- Other significant cormorbidities.